These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

142 related items for PubMed ID: 11672464

  • 1. Risk factors for toxoplasmic encephalitis in HIV-infected patients: a case-control study in Brazil.
    Nascimento LV, Stollar F, Tavares LB, Cavasini CE, Maia IL, Cordeiro JA, Ferreira MU.
    Ann Trop Med Parasitol; 2001 Sep; 95(6):587-93. PubMed ID: 11672464
    [Abstract] [Full Text] [Related]

  • 2. Comparison of high and low doses of trimethoprim-sulfamethoxazole for primary prevention of toxoplasmic encephalitis in human immunodeficiency virus-infected patients.
    Ribera E, Fernandez-Sola A, Juste C, Rovira A, Romero FJ, Armadans-Gil L, Ruiz I, Ocaña I, Pahissa A.
    Clin Infect Dis; 1999 Dec; 29(6):1461-6. PubMed ID: 10585796
    [Abstract] [Full Text] [Related]

  • 3. [Incidence of bacterial pneumonia in HIV-positive patients treated with preventive co-trimoxazole or pentamidine].
    Koch A, Kothe H, Braun J, Kämmerer R, Friedrich HJ, Dalhoff K.
    Pneumologie; 1998 Nov; 52(11):614-21. PubMed ID: 9885511
    [Abstract] [Full Text] [Related]

  • 4. Discontinuation of primary prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus type I-infected patients: the changes in opportunistic prophylaxis study.
    Mussini C, Pezzotti P, Govoni A, Borghi V, Antinori A, d'Arminio Monforte A, De Luca A, Mongiardo N, Cerri MC, Chiodo F, Concia E, Bonazzi L, Moroni M, Ortona L, Esposito R, Cossarizza A, De Rienzo B.
    J Infect Dis; 2000 May; 181(5):1635-42. PubMed ID: 10823763
    [Abstract] [Full Text] [Related]

  • 5. [Highly Active AntiRetroviral Therapy and opportunistic protozoan infections].
    Pozio E.
    Parassitologia; 2004 Jun; 46(1-2):89-93. PubMed ID: 15305694
    [Abstract] [Full Text] [Related]

  • 6. Clinical presentation and outcome of toxoplasmic encephalitis in patients with human immunodeficiency virus type 1 infection.
    Ho YC, Sun HY, Chen MY, Hsieh SM, Sheng WH, Chang SC.
    J Microbiol Immunol Infect; 2008 Oct; 41(5):386-92. PubMed ID: 19122919
    [Abstract] [Full Text] [Related]

  • 7. Effectiveness of twice-weekly pyrimethamine-sulfadoxine as primary prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis in patients with advanced HIV infection.
    Schürmann D, Bergmann F, Albrecht H, Padberg J, Wünsche T, Grünewald T, Schürmann M, Grobusch M, Vallée M, Ruf B, Suttorp N.
    Eur J Clin Microbiol Infect Dis; 2002 May; 21(5):353-61. PubMed ID: 12072919
    [Abstract] [Full Text] [Related]

  • 8. HIV-associated Isospora belli infection: incidence and risk factors in the French Hospital Database on HIV.
    Guiguet M, Furco A, Tattevin P, Costagliola D, Molina JM, French Hospital Database on HIV Clinical Epidemiology Group.
    HIV Med; 2007 Mar; 8(2):124-30. PubMed ID: 17352769
    [Abstract] [Full Text] [Related]

  • 9. Toxoplasmic encephalitis in acquired immunodeficiency syndrome.
    Chaddha DS, Kalra SP, Singh AP, Gupta RM, Sanchetee PC.
    J Assoc Physicians India; 1999 Jul; 47(7):680-4. PubMed ID: 10778586
    [Abstract] [Full Text] [Related]

  • 10. A preliminary study of the frequency of focal neurological deficits in HIV/AIDS patients seropositive for Toxoplasma gondii IgG in Lagos, Nigeria.
    Oshinaike OO, Okubadejo NU, Ojini FI, Danesi MA.
    Nig Q J Hosp Med; 2010 Jul; 20(3):104-7. PubMed ID: 21033315
    [Abstract] [Full Text] [Related]

  • 11. Discontinuation of primary and secondary Toxoplasma gondii prophylaxis is safe in HIV-infected patients after immunological restoration with highly active antiretroviral therapy: results of an open, randomized, multicenter clinical trial.
    Miro JM, Lopez JC, Podzamczer D, Peña JM, Alberdi JC, Martínez E, Domingo P, Cosin J, Claramonte X, Arribas JR, Santín M, Ribera E, GESIDA 04/98 Study Group.
    Clin Infect Dis; 2006 Jul 01; 43(1):79-89. PubMed ID: 16758422
    [Abstract] [Full Text] [Related]

  • 12. Incidence and risk factors of toxoplasmosis in a cohort of human immunodeficiency virus-infected patients: 1988-1995. HEMOCO and SEROCO Study Groups.
    Belanger F, Derouin F, Grangeot-Keros L, Meyer L.
    Clin Infect Dis; 1999 Mar 01; 28(3):575-81. PubMed ID: 10194081
    [Abstract] [Full Text] [Related]

  • 13. Randomized controlled trial of pyrimethamine plus sulfadiazine versus trimethoprim plus sulfamethoxazole for treatment of toxoplasmic encephalitis in AIDS patients.
    Kongsaengdao S, Samintarapanya K, Oranratnachai K, Prapakarn W, Apichartpiyakul C.
    J Int Assoc Physicians AIDS Care (Chic); 2008 Mar 01; 7(1):11-6. PubMed ID: 17517949
    [Abstract] [Full Text] [Related]

  • 14. Toxoplasmosis in HIV/AIDS patients: a current situation.
    Nissapatorn V, Lee C, Quek KF, Leong CL, Mahmud R, Abdullah KA.
    Jpn J Infect Dis; 2004 Aug 01; 57(4):160-5. PubMed ID: 15329448
    [Abstract] [Full Text] [Related]

  • 15. Incidence and risk factors for toxoplasmic encephalitis in human immunodeficiency virus-infected patients before and during the highly active antiretroviral therapy era.
    Abgrall S, Rabaud C, Costagliola D, Clinical Epidemiology Group of the French Hospital Database on HIV.
    Clin Infect Dis; 2001 Nov 15; 33(10):1747-55. PubMed ID: 11595976
    [Abstract] [Full Text] [Related]

  • 16. Prevalence, associated factors, and prognostic determinants of AIDS-related toxoplasmic encephalitis in the era of advanced highly active antiretroviral therapy.
    Antinori A, Larussa D, Cingolani A, Lorenzini P, Bossolasco S, Finazzi MG, Bongiovanni M, Guaraldi G, Grisetti S, Vigo B, Gigli B, Mariano A, Dalle Nogare ER, De Marco M, Moretti F, Corsi P, Abrescia N, Rellecati P, Castagna A, Mussini C, Ammassari A, Cinque P, d'Arminio Monforte A, Italian Registry Investigative NeuroAIDS.
    Clin Infect Dis; 2004 Dec 01; 39(11):1681-91. PubMed ID: 15578371
    [Abstract] [Full Text] [Related]

  • 17. Twice-weekly pyrimethamine-sulfadoxine effectively prevents Pneumocystis carinii pneumonia relapse and toxoplasmic encephalitis in patients with AIDS.
    Schürmann D, Bergmann F, Albrecht H, Padberg J, Grünewald T, Behnsch M, Grobusch M, Vallée M, Wünsche T, Ruf B, Suttorp N.
    J Infect; 2001 Jan 01; 42(1):8-15. PubMed ID: 11243747
    [Abstract] [Full Text] [Related]

  • 18. Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy.
    Kaufmann GR, Furrer H, Ledergerber B, Perrin L, Opravil M, Vernazza P, Cavassini M, Bernasconi E, Rickenbach M, Hirschel B, Battegay M, Swiss HIV Cohort Study.
    Clin Infect Dis; 2005 Aug 01; 41(3):361-72. PubMed ID: 16007534
    [Abstract] [Full Text] [Related]

  • 19. [Epidemiologic characteristics of cerebral toxoplasmosis in 399 HIV-infected patients followed between 1983 and 1994].
    Bossi P, Caumes E, Astagneau P, Li TS, Paris L, Mengual X, Katlama C, Bricaire F.
    Rev Med Interne; 1998 May 01; 19(5):313-7. PubMed ID: 9775164
    [Abstract] [Full Text] [Related]

  • 20. Risk of toxoplasmic encephalitis in AIDS patients: indications for prophylaxis.
    Dunlop O, Rootwelt V, Sannes M, Goplen AK, Abdelnoor M, Skaug K, Baklien K, Skar A, Melby K, Myrvang B, Bruun JN.
    Scand J Infect Dis; 1996 May 01; 28(1):71-3. PubMed ID: 9122637
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.